SLE-Associated Thrombocytopaenia — RACP Adult Medicine MCQ
Instant feedback + full explanation. One question, done properly.
Educational content. Not a substitute for clinical judgement or local policy.
Reveal the answer and explanation
Correct answer: B — ITP secondary to SLE
SLE-associated immune thrombocytopaenia (secondary ITP) occurs in up to 25% of SLE patients. It results from autoimmune destruction of platelets (anti-platelet antibodies) with adequate bone marrow megakaryocytes. The negative Coombs test and absence of haemolysis distinguish it from Evans syndrome (combined AIHA + ITP). Treatment follows SLE management principles: corticosteroids first-line, hydroxychloroquine continuation, and rituximab or IVIg for refractory cases.
Reference: eTG – 2025 – Rheumatology; ASH – 2019 – ITP Guidelines